bridget o'keeffe

“After decades of research into the potential of cytokines to elicit antitumor immune responses, checkpoint inhibition appears to have made room for a new coming of age for cytokine therapy. It’s exciting to see the development of new technologies that can more precisely leverage the power and beauty of cytokine biology in this new era of cancer immunotherapy.” 

Bridget O’Keeffe
Vice President Clinical Development
OncoSec Medical 

michael schmidt

“Good opportunity to learn above novel approaches to improve the therapeutic window of cytokine drugs”

Michael Schmidt
Chief Scientific Officer
Ankyra Therapeutics

michael atkins

“It is important to examine the potential.  This meeting will provide detailed presentations and discussion about the promising new approaches for using  cytokines to improve the antitumor efficacy of checkpoint inhibitor based immunotherapy.”

Michael B. Atkins
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center Scholl Professor and Vice Chair, Department of Oncology
Georgetown University Medical Center

roberto de luca

“Cytokines are immunomodulatory proteins that have been considered for pharmaceutical applications in the treatment of cancer patients and other types of disease. There is a growing interest in the use of engineered cytokine products as anticancer drugs, capable of boosting the action of T cells and natural killer (NK) cells against tumors, alone or in combination with immune checkpoint inhibitors.”

Roberto De Luca
Head of therapeutic antibodies

jamie S

This meeting brings together leaders in cytokine biology, therapeutic design, and immune oncology to collectively advance the development of targeted and effective cancer drugs. 

Jamie Spangler
Assistant Professor

Johns Hopkins University